NFA
RNTX

Nationwide Fund Advisors’s Rein Therapeutics RNTX Stock Holding History

Nationwide Fund Advisors’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-127
Closed -$34K – 2195
2017
Q3 		$34K Buy
+127
New +$31.9K ﹤0.01% 3076

Other funds holding RNTX

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nationwide Fund Advisors's RNTX Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Rein Therapeutics (RNTX) in Q4 2017, closing a stake of 127 shares — an estimated $34K sold.

Nationwide Fund Advisors first reported a position in RNTX in Q3 2017 and held it in 1 quarter. The position peaked at $34K in Q3 2017. 33 funds tracked by Wall St. Rank hold RNTX as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining Rein Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 127 Rein Therapeutics shares in Q4 2017, an estimated $34K.
  • Nationwide Fund Advisors first reported a position in Rein Therapeutics in Q3 2017 and held it in 1 quarter.
  • Nationwide Fund Advisors's Rein Therapeutics position peaked at $34K in Q3 2017.
  • 33 funds tracked by Wall St. Rank held Rein Therapeutics as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.